3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
60
Breast Neoplasms
21
Neoplasms
19
Fallopian Tube Neoplasms
16
Prostatic Neoplasms
15
Neoplasm Metastasis
9
Pancreatic Neoplasms
8
Endometrial Neoplasms
8
Glioblastoma
7
Triple Negative Breast Neoplasms
6
Lung Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Small Cell Lung Carcinoma
4
Glioma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Mesothelioma
3
Melanoma
3
Head and Neck Neoplasms
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Sarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Diseases
2
Mesothelioma, Malignant
2
Interventions
Bevacizumab
5
pembrolizumab
4
Gemcitabine
4
Cisplatin
4
napabucasin
3
Paclitaxel
3
Irinotecan
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
entinostat
2
anlotinib
2
Taxes
2
Sunitinib
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
Ocoxin
2
Leucovorin
2
Immunotherapy
2
Fluorouracil
2
Carboplatin
2
sipuleucel-T
1
pralsetinib
1
palbociclib
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
linifanib
1
lenvatinib
1
ixabepilone
1
interferon gamma-1b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Glandular and Epithelial
×
niraparib
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled